Physician profile
Thinesh Dahanayake
NPI 1639293186
$191,988.17
in general payments reported to CMS, 2019-2025
47 companies · $98K in 2025
The $98K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,988 · 2021: $1,926 · 2022: $13K · 2023: $13K · 2024: $53K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Consulting Fee: $41K · Travel and Lodging: $12K · Food and Beverage: $11K · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,983.40 |
| Consulting Fee | $40,531.64 |
| Travel and Lodging | $11,849.50 |
| Food and Beverage | $11,041.41 |
| Education | $190.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $153,578.76 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $14,219.93 | 2019-2025 | Dupixent |
| Insmed, INC. | $6,464.32 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $5,257.54 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $3,264.46 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Janssen Pharmaceuticals, INC | $1,474.96 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,157.04 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $687.52 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Mallinckrodt Hospital Products INC. | $627.42 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $524.16 | 2019-2024 | Yupelri, Yupelri |
| Novartis Pharmaceuticals Corporation | $400.14 | 2019-2024 | |
| Harmony Biosciences LLC | $382.41 | 2020-2025 | Wakix |
| Amgen INC. | $349.87 | 2021-2025 | Tezspire |
| Alexion Pharmaceuticals, INC. | $291.28 | 2019-2023 | Ultomiris |
| Pfizer INC. | $262.33 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $246.78 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $242.06 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $238.90 | 2020-2025 | Cuvitru, Glassia |
| Grifols USA, LLC | $215.95 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Sunovion Pharmaceuticals INC. | $180.10 | 2019 | |
| Electromed, INC. | $157.24 | 2024-2025 | Smartvest |
| Mallinckrodt Enterprises LLC | $153.10 | 2019 | |
| Portola Pharmaceuticals, LLC | $143.94 | 2019 | |
| Advanced Respiratory, INC | $140.03 | 2019 | |
| Verona Pharma, INC. | $107.18 | 2025 | Ohtuvayre |
| Philips North America LLC | $104.87 | 2019-2025 | Vest Therapy Und |
| Ethicon INC. | $103.71 | 2020 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Merck Sharp & Dohme LLC | $89.13 | 2019-2025 | Winrevair |
| Boston Scientific Corporation | $87.51 | 2020-2022 | |
| Baxter Healthcare | $81.63 | 2023-2025 | Hillrom - Life 2000 Ventilation System |
| Inspire Medical Systems, INC. | $78.32 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $73.35 | 2023-2025 | Sunosi |
| Circassia INC. | $71.94 | 2019 | |
| Genentech USA, INC. | $70.04 | 2019-2025 | Xolair |
| Zoll Respicardia, INC. | $56.11 | 2025 | Remede System |
| Viatris Specialty LLC | $49.40 | 2025 | Yupelri |
| Lilly USA, LLC | $43.44 | 2023-2025 | Jardiance |
| Inogen, INC. | $35.71 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Csl Behring | $32.19 | 2019-2020 | |
| Phadia US INC. | $31.54 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $24.06 | 2025 | Neffy |
| Gilead Sciences, INC. | $22.33 | 2022 | |
| Vapotherm INC | $21.63 | 2022 | |
| Vifor Pharma, INC. | $20.33 | 2024 | Zemaira |
| Pulmonx Corporation | $13.07 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thinesh Dahanayake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.